These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19489219)

  • 21. Targeting survivin's co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy?
    Holloway MP; Altura RA
    Future Oncol; 2012 Aug; 8(8):907-9. PubMed ID: 22894664
    [No Abstract]   [Full Text] [Related]  

  • 22. Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients.
    Altundag K
    J BUON; 2019; 24(5):2206. PubMed ID: 31786897
    [No Abstract]   [Full Text] [Related]  

  • 23. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer in focus: treatment options for triple-negative metastatic breast cancer.
    O'Shaughnessy JA
    Clin Adv Hematol Oncol; 2012 Jan; 10(1):43-5. PubMed ID: 22398807
    [No Abstract]   [Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mouse models of triple negative [basal-like/claudin low] breast cancer.
    Herschkowitz JI; Lubet R
    Breast Dis; 2010; 32(1-2):63-71. PubMed ID: 21965308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
    Wang N; Wang YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
    [No Abstract]   [Full Text] [Related]  

  • 28. Triple-negative breast cancer and brain metastases.
    Sait B; Cinar E; Altundag K
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969
    [No Abstract]   [Full Text] [Related]  

  • 29. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
    Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
    J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
    [No Abstract]   [Full Text] [Related]  

  • 30. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 32. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.
    Koo JS; Jung W; Yang WI
    Int J Surg Pathol; 2011 Aug; 19(4):425-32. PubMed ID: 19666946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
    Frederik P; Cecile C; Tjalma WA
    Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.
    Duffy MJ; McDermott EW; Crown J
    Clin Chem; 2017 Apr; 63(4):804-806. PubMed ID: 28188230
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
    Ganesan S; Karantza V; Oza J; Toppmeyer D
    Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular predictors of response to therapy for breast cancer.
    Galanina N; Bossuyt V; Harris LN
    Cancer J; 2011; 17(2):96-103. PubMed ID: 21427553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 40. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.